Maternal serum ADAM12s in the late first trimester of pregnancies with Trisomy 21

ADAM12s is a placenta‐derived glycoprotein that is involved in growth and differentiation, and has been shown to be a potential first‐trimester and second‐trimester marker of Trisomy 21 and other aneuploides. Maternal ADAM12s concentrations show a considerable temporal variation with gestational age and here we study the levels at 11–13 weeks of gestation to establish the effectiveness or otherwise at a time when other established markers are used.

[1]  K. Spencer,et al.  Maternal serum ADAM12s as a marker of rare aneuploidies in the first or second trimester of pregnancy , 2007, Prenatal diagnosis.

[2]  K. Spencer,et al.  First‐trimester ADAM12 and PAPP‐A as markers for intrauterine fetal growth restriction through their roles in the insulin‐like growth factor system , 2007, Prenatal diagnosis.

[3]  K. Spencer,et al.  ADAM12 as a marker of trisomy 18 in the first and second trimester of pregnancy , 2007, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[4]  K. Spencer,et al.  ADAM 12 as a second‐trimester maternal serum marker in screening for Down syndrome , 2006, Prenatal diagnosis.

[5]  K. Spencer,et al.  ADAM 12 as a first‐trimester maternal serum marker in screening for Down syndrome , 2006, Prenatal diagnosis.

[6]  H. Cuckle,et al.  Maternal serum ADAM12 levels in Down and Edwards' syndrome pregnancies at 9–12 weeks' gestation , 2006, Prenatal diagnosis.

[7]  B. No̸rgaard-Pedersen,et al.  Reduction of the Disintegrin and Metalloprotease ADAM12 in Preeclampsia , 2005, Obstetrics and gynecology.

[8]  M. Christiansen,et al.  The level of ADAM12‐S in maternal serum is an early first‐trimester marker of fetal trisomy 18 , 2005, Prenatal diagnosis.

[9]  N. Uldbjerg,et al.  ADAM12: a novel first‐trimester maternal serum marker for Down syndrome , 2003, Prenatal diagnosis.

[10]  K. Nicolaides,et al.  A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free β‐hCG and PAPP‐A , 2002, Prenatal diagnosis.

[11]  J. Fox,et al.  ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. , 2000, Biochemical and biophysical research communications.

[12]  F. Loechel,et al.  ADAM 12, a Disintegrin Metalloprotease, Interacts with Insulin-like Growth Factor-binding Protein-3* , 2000, The Journal of Biological Chemistry.

[13]  K. Nicolaides,et al.  A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free β‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐A , 1999, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[14]  K. Nicolaides,et al.  Maternal age‐ and gestation‐specific risk for trisomy 21 , 1999, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[15]  K. Nicolaides,et al.  UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation , 1998, The Lancet.

[16]  E. Engvall,et al.  A Novel, Secreted Form of Human ADAM 12 (Meltrin α) Provokes Myogenesis in Vivo * , 1998, The Journal of Biological Chemistry.